Summary & Overview
HCPCS E0737: Transcutaneous Tibial Nerve Stimulator, Phone-Controlled
HCPCS Level II code E0737 designates a transcutaneous tibial nerve stimulator controlled by a phone application, a durable medical equipment neuromodulation device used to manage lower urinary tract dysfunction in outpatient and home settings. The code reflects the growing role of digitally enabled neuromodulation devices that allow patients to self-administer therapy under clinical guidance.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national overview of coverage and reimbursement themes, common billing practices, and clinical context for the device’s use. The publication summarizes benchmark payment patterns, common modifier usage, and payer-specific policy considerations where available. It also outlines the clinical indications driving utilization and practical site-of-service implications for home-based, app-controlled neuromodulation.
This report is intended for revenue cycle leaders, clinicians, and policy analysts seeking concise guidance on coding and billing context for HCPCS Level II code E0737, including where to look for payer policy updates and how the device fits into outpatient and home-based care pathways.
Billing Code Overview
HCPCS Level II code E0737 represents a transcutaneous tibial nerve stimulator, controlled by phone application. This device delivers percutaneous or transcutaneous electrical stimulation targeting the tibial nerve to manage lower urinary tract dysfunction via neuromodulation.
-
Service Type: Durable medical equipment (DME) neuromodulation device
-
Typical Site of Service: Outpatient, home-based use with remote control via a phone application
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with refractory overactive bladder (OAB) presents to a urology clinic after failing behavioral therapy and multiple antimuscarinic medications due to insufficient symptom control and intolerable side effects. A transcutaneous tibial nerve stimulator controlled by a phone application is prescribed as a neuromodulation option. The patient attends an initial in-clinic education and device setup visit where the clinician reviews indications, demonstrates electrode placement over the posterior tibial nerve near the medial malleolus, and pairs the disposable or reusable stimulator to the patient’s smartphone application. The visit includes baseline symptom assessment, instructions for daily home use sessions (typically 20–30 minutes, multiple times per week), troubleshooting, and documentation of consent and device settings.
Follow-up occurs via scheduled telehealth or in-person visits at 4–8 weeks to assess response, adherence, and side effects. Device-controlled stimulation sessions are performed by the patient at home using the mobile app; data may be transmitted to the clinic for review. Typical workflow tasks documented in the medical record include indication (OAB or urgency urinary incontinence), prior conservative management, device training, device pairing and programming, patient-reported outcomes, and plans for continuation or escalation of therapy if inadequate response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |